GSK plc
GSKNYSEHealthcare● Active
$50.89
$-0.64(-1.23%)
Market Cap$102.3B
P/E Ratio—
52W High$61.7
52W Low$35.45
GSK plc（GSK）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GSK · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $32.67B | $31.38B | $30.33B | $29.32B | $24.70B |
| Cost of Revenue | $9.02B | $9.05B | $8.56B | $9.55B | $8.16B |
| Gross Profit | $23.65B | $22.33B | $21.76B | $19.77B | $16.53B |
| Gross Margin %(computed) | 72.40% | 71.16% | 71.76% | 67.42% | 66.95% |
| Operating Expenses | |||||
| R&D Expenses | $7.53B | $6.40B | $6.22B | $5.49B | $5.02B |
| G&A Expenses | $9.09B | $11.02B | $9.38B | $8.37B | $7.07B |
| Total Operating Expenses | $15.31B | $18.31B | $15.02B | $13.34B | $12.18B |
| Operating Income | $8.34B | $4.02B | $6.75B | $6.43B | $4.36B |
| Operating Margin %(computed) | 25.52% | 12.82% | 22.24% | 21.94% | 17.64% |
| Interest Income | $0.06B | $0.07B | $0.04B | $0.06B | $0.03B |
| Interest Expense | $0.69B | $0.66B | $0.78B | $0.86B | $0.78B |
| Income Before Tax | $7.40B | $3.48B | $6.06B | $5.63B | $3.60B |
| Income Tax Expense | $1.11B | $0.53B | $0.76B | $0.71B | $0.08B |
| Net Income | $5.72B | $2.58B | $4.93B | $14.96B | $4.38B |
| Net Margin %(computed) | 17.50% | 8.21% | 16.25% | 51.00% | 17.76% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $5.64 | $1.26 | $2.44 | $7.44 | $2.74 |
| Wtd Avg Shares | 1.01B | 2.04B | 2.03B | 2.01B | 1.60B |
| EBITDA | $10.40B | $6.67B | $9.08B | $8.60B | $6.49B |
| EBITDA Margin %(computed) | 31.84% | 21.25% | 29.95% | 29.33% | 26.26% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · GBP · B
深入了解GSK plc
关于GSK plc（GSK）损益表
GSK plc（GSK）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，GSK实现营收$32.67B，毛利润$23.65B（毛利率72.40%），净利润$5.72B（净利率17.50%）。
常见问题
GSK · 4 问GSK plc（GSK）2025财年营收为$32.67B，同比up4.1%。
GSK revenueGSK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08